THERMOGENESIS HOLDINGS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6 USD | -1.90% |
|
-17.67% | -6.82% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 10.48M | Sales 2023 | 9.44M | Capitalization | 1.89M |
|---|---|---|---|---|---|
| Net income 2022 | -11M | Net income 2023 | -18M | EV / Sales 2022 | 0.97 x |
| Net Debt 2022 | 6.89M | Net Debt 2023 | 9.28M | EV / Sales 2023 | 1.18 x |
| P/E ratio 2022 |
-0.16
x | P/E ratio 2023 |
-0.08
x | Employees | 25 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on ThermoGenesis Holdings, Inc.
More press releases
| 1 day | -8.44% | ||
| 1 week | -17.67% | ||
| Current month | -18.38% | ||
| 1 month | -13.85% | ||
| 3 months | -47.42% | ||
| 6 months | -42.86% | ||
| Current year | -6.82% |
1 week
0.52
0.70
1 month
0.520.76
Current year
0.361.25
1 year
0.361.84
3 years
0.36142.20
5 years
0.36638.10
10 years
0.3618 359.12
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
Jeffery Cauble
DFI | Director of Finance/CFO | 51 | 09-12-31 |
Wendy Samford
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Medford
BRD | Director/Board Member | 69 | 17-02-23 |
Joseph Thomis
BRD | Director/Board Member | 78 | 17-01-09 |
Xiao Chun Xu
CEO | Chief Executive Officer | 53 | 16-03-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.6 | -1.90% | 32 648 |
| 24-05-20 | 0.6116 | +4.21% | 14,412 |
| 24-05-17 | 0.5869 | +12.74% | 63,028 |
| 24-05-16 | 0.5206 | -19.91% | 101,406 |
| 24-05-15 | 0.65 | -4.44% | 14,970 |
Delayed Quote Nasdaq, May 21, 2024 at 10:07 am EDT
More quotes
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Sector
Office Equipment
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.82% | 4.86M | |
| +9.28% | 8.21B | |
| -3.38% | 4.69B | |
| -4.61% | 2.98B | |
| +8.35% | 2.16B | |
| -28.04% | 1.1B | |
| +12.45% | 1.06B | |
| -3.29% | 855M | |
| -23.22% | 755M | |
| -53.81% | 732M |
- Stock Market
- Equities
- THMO Stock
